[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$515b

Top Social Posts

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"Wall Street doubters underestimated $JNJs 3Q-2025 rebound after last years lull. * Revenue: $24.0B up XXX% year-over-year and XXX% above expectations * Adjusted EPS: $XXXX up XXXX% year-over-year and XXX% above expectations * Net earnings surged XX% to $5.15B * Raised 2025 sales guidance to $93.7B Revenue and profit both beat expectations reversing prior year weakness. Growth is supported by new product launches in oncology and immunology. Increased guidance indicates confidence despite higher tax costs. Earnings call is scheduled for today at 08:30 am EDT"
X Link @marvin_labs 2025-10-14T11:33Z XXX followers, XX engagements

"$JNJ Q3 '25: Net inc $5.15b EPS $XXXX (Adj EPS $2.80) Rev $24b +6.8% YoY Op growth +5.4% Adj op growth +4.4% INLEXZO & TREMFYA approvals pipeline progress Raises FY25 rev guide to $93.7b (+5.7%) reaffirms adj EPS $10.85"
X Link @FwdQuarter 2025-10-14T11:25Z 1100 followers, XX engagements

"Johnson & Johnson $JNJ Q3-25. Results: 📊 Adj. EPS: $XXXX 🟢 💰 Revenue: $24.0B 🟢 📈 Net Income: $5.15B 🔎 Strong pipeline progress and product approvals drove XX% jump in net income; 2025 sales outlook raised to $93.7B"
X Link @Earnings_Time 2025-10-14T10:29Z 12.2K followers, 13.9K engagements

"$JNJ Johnson & Johnson Q3 2025 Solid Beat on EPS and Sales; Outlook Raised Adjusted EPS: $XXXX vs. $XXXX expected ✅ Revenue: $24.0B vs. $23.76B expected ✅ Net Earnings: $5.15B (+91% YoY) Reported EPS: $XXXX (+91% YoY) Innovative Medicine Sales: $15.56B (+6.8% YoY) MedTech Sales: $8.43B (+6.8% YoY) Full-Year Sales Outlook: Raised to $93.7B (midpoint +5.7%) FY Adjusted EPS Guidance: Reaffirmed at $XXXXX Johnson & Johnson delivered another solid quarter with both top- and bottom-line results surpassing expectations. Growth was driven by oncology (Darzalex Carvykti) immunology (Tremfya) and"
X Link @allday_stocks 2025-10-14T10:21Z 1464 followers, XXX engagements